NCT04709835View on ClinicalTrials.gov

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

September 17, 2021

Study Completion Date

October 13, 2021

Conditions
COVID-19
Interventions
DRUG

AT-527

Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg.

DRUG

Placebo

The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.

Trial Locations (12)

15

Connolly Hospital, Dublin

28031

Hospital Universitario Infanta Leonor, Madrid

280146

Hospital Universitario La Paz, Madrid

L8M 1K7

Hamilton Medical Research Group, Hamilton

115 28

National and Kapodistrian University of Athens, Athens

184 54

General State Hospital of Nikaia St Panteleimon, Nikaia Attikis

LV-1011

Outpatient Clinic Adoria, Riga

LV-2121

The Family Physician's Practice of Dr. Maija Kozlovska, Salaspils

OL6 6EW

Chapel Street Medical Centre, Ashton-under-Lyne

BL9 0NJ

Tower Family Healthcare - Moorgate Primary Care Ce, Bury

G20 0XA

CPS Research, Glasgow

SW3 6JJ

Chelsea and Westminster NHS Trust, London

Sponsors
All Listed Sponsors
collaborator

Atea Pharmaceuticals, Inc.

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT04709835 - Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 | Biotech Hunter | Biotech Hunter